Skip to main content
SP5007,677.28+0.32%DOW53,577.40+0.30%NASDAQ26,151.30+0.66%BTC$78,217.00-0.96%ETH$2,437.95-1.69%GOLD$4,716.60+0.40%OIL$81.06-4.65%
Smart Investors Daily
Sign InSign Up Free
FI

NASDAQ · FIXX

Homology Medicines, Inc.

Healthcare · Biotechnology

$12.74

Down-$0.18 (-1.45%)

Updated Aug 25, 2026, 9:09 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.02M
P/E ratio
-0.93
Dividend yield
0.00%
52-week range
— – —
Volume
364
Avg. volume
29.54K

Price performance

FIXX price history

1M range · 4 trading sessions · Daily adjusted prices

FIXX closed at $12.74 after 4 trading sessions, down 9.92% for the selected period.

Last close
$12.74
Period change
-9.92%
Period low
$12.74
Period high
$14.15
Daily close
View OHLC price history
FIXX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 24, 2026$12.7447$12.7447$12.7447$12.7447364
Aug 21, 2026$13.5239$13.5239$13.5239$13.5239135
Aug 20, 2026$14.30$14.30$13.73$13.8236855
Aug 19, 2026$14.05$14.1481$13.79$14.14812.47K

Latest FIXX news

The latest Smart Investors Daily articles mentioning FIXX.

Stock researchCompany · Overview

FIXX research

Overview

Company profile and research snapshot.

Company profile

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.70
Implied upside
—
Analysts
—
FIXX recent ratings
DateFirmRatingTarget
Jul 28, 2023BairdNeutral—
May 15, 2023HC Wainwright & Co.Buy—
May 12, 2023Credit SuisseNeutral—
May 12, 2023Chardan CapitalBuy—
Mar 16, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Mar 18, 2024

Homology Medicines Declares Distribution to Common Stockholders

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date for such distribution is expected to be March 27, 2024 (three business days after the expected closing of the merger on March 22, 2024). Each CVR represents the non-transferable contractual right to receive certain contingent payments upon the occurrence of certain events within agreed time periods as provided in the merger agreement and agreement governing the CVRs.

Benzinga · Nov 16, 2023

Gold Gains 1%; Williams-Sonoma Posts Upbeat Earnings

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 100 points on Thursday. The Dow traded down 0.39% to 34,853.42 while the NASDAQ fell 0.11% to 14,087.96. The S&P 500 also fell, dropping, 0.09% to 4,498.85. Check This Out: Top 4 Financial Stocks You'll Regret Missing This Month   Leading and Lagging Sectors   Utilities shares surged by 1% on Thursday. In trading on Thursday, energy shares fell by 2.2%.   Top Headline   Williams-Sonoma, Inc. (NYSE: WSM) reported better-than-expected third-quarter adjusted earnings. Williams-Sonoma posted non-GAAP earnings of $3.66 per share, versus market estimates of $3.35 per share. The company’s quarterly sales came in at $1.854 billion versus expectations of $1.957 billion.   Equities Trading UP   Sonos, Inc. (NASDAQ: SONO) shares shot up 18% to $13.37 following upbeat fourth-quarter results. Shares of WaveDancer, Inc. (NASDAQ: WAVD) got a boost, shooting 68% to $2.53 after the company inked a definitive merger agreement with Firefly Neuroscience in an all-stock transaction. Universal Technical Institute, Inc. (NYSE: ...

Benzinga · Nov 16, 2023

Crude Oil Down 4%; Walmart Shares Fall After Q3 Results

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.40% to 34,850.49 while the NASDAQ fell 0.35% to 14,055.15. The S&P 500 also fell, dropping, 0.23% to 4,492.60. Check This Out: Top 4 Financial Stocks You'll Regret Missing This Month   Leading and Lagging Sectors   Utilities shares surged by 1% on Thursday. In trading on Thursday, energy shares fell by 2.2%.   Top Headline   Shares of Walmart Inc (NYSE: WMT) fell around 7% on Thursday after the company reported results for the third quarter. Walmart reported third-quarter FY24 sales growth of 5.2% year-over-year to $160.8 billion, beating the consensus of $159.55 billion. Adjusted EPS was $1.53, above $1.50 last year same quarter, beating the consensus of $1.52. For FY24, Walmart now sees adjusted EPS guidance of $6.40-$6.48 (prior 6.36-$6.46) versus an estimate of $6.48. The company raised its FY24 net sales growth (cc) outlook to 5.0% to 5.5% from 4% - 4.5% earlier.   Equities Trading UP   Sonos, Inc. (NASDAQ: SONO) shares shot up 17% to $13.28 following upbeat fourth-quarter results. Shares of WaveDancer, Inc. (NASDAQ:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By